Allergan

Named as a key player in 396 of our reports, across 33 regions and countries.

[1] ClinicalTrials.gov, Studies led by Allergan or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.

Recent reports naming Allergan

Our newest markets with them as a key player. Each covers 2024 history, a 2025 base year and forecasts to 2034.

All 396 reports

Companies they compete with most

Named as key players in the same markets as Allergan (number of shared markets).

Public data

Free public data on Allergan

From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.

About our sources

Company facts

Home country
Ireland
Stock listing
NYSE: AGN
Legal name
Allergan plc
Type
Medicines

Source: Wikidata, Company record Q906187. Retrieved 13 Nov 2026.

Source: GLEIF, Legal entity record, LEI 635400FWJZQC1IPYUH69. Retrieved 13 Nov 2026.

Source: SEC EDGAR, Company filings, CIK 1578845. Retrieved 13 Nov 2026.

US device clearances

12 510(k) clearances and PMA approvals since 2015

Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Retrieved 13 Nov 2026.

See them on openFDA (opens in a new tab)

Trials over time

Studies Allergan leads, by the year they started and their phase

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • No phase (devices, observational)

Source: ClinicalTrials.gov, Studies with Allergan or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.

Search all reports for Allergan All companies